Lexaria Bioscience Corp. (NASDAQ:LEXX – Free Report) – Research analysts at Zacks Small Cap lifted their FY2024 earnings estimates for shares of Lexaria Bioscience in a research report issued on Monday, April 29th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will earn ($0.46) per share for the year, up from their […]
Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) and Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Analyst Recommendations This is a summary of […]
Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) and Edesa Biotech (NASDAQ:EDSA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends. Volatility & Risk Lexaria Bioscience has a […]
Invenomic Capital Management LP raised its stake in Lexaria Bioscience Corp. (NASDAQ:LEXX – Free Report) by 62.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 766,573 shares of the company’s stock after buying an additional 293,470 shares during the quarter. Invenomic Capital Management LP owned approximately 9.48% […]
Lexaria Bioscience Corp. (NASDAQ:LEXX – Get Free Report) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 422,900 shares, an increase of 14.5% from the September 15th total of 369,200 shares. Approximately 5.8% of the shares of the company are […]